You are here: Industry Insights > AT-100

News List

Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients firstwordpharma
August 27, 2021
Airway Therapeutics, Inc. (Airway) announced dosing of the first patient on August 17, 2021 in the AT-100 (rhSP-D) Phase 1b trial in mechanically-ventilated COVID-19 patients.
Airway Therapeutics Announces FDA Acceptance of IND for AT-100's Second Indication in Severe COVID-19 Patients prnasia
April 12, 2021
Airway Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to develop AT-100 (rhSP-D) as a treatment for COVID-19.
Airway Announces IND Acceptance of AT-100 for Preterm Infants at Risk for BPD americanpharmaceuticalreview
April 02, 2021
Airway Therapeutics announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to develop AT-100 (rhSP-D) as a preventive treatment for the serious respiratory disease BPD in very preterm babies.
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD) prnasia
March 26, 2021
Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, today announced the U.S. Food and Drug Administration ...
Airway Therapeutics and Celonic Enter COVID-19 Collaboration contractpharma
May 26, 2020
Will make AT-100 as promising new candidate for coronavirus, production expected to begin in June.